Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|STM434||STM 434|STM-434||STM434 is a fusion protein comprising the extracellular domain of activin type II B receptor (ACVR2B) linked to a Fc chain that binds to activin-A and blocks activation of ACVR2B signaling, which potentially inhibits proliferation, survival and migration of activin-A overexpressing cancer cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||granulosa cell tumor||no benefit||STM434||Phase I||Actionable||In a Phase I trial, STM 434 treatment did not result in response in 30 evaluable patients with advanced solid tumors and only resulted in stable disease as best response in 80% (10/12) of patients with granulosa cell ovarian cancer (PMID: 31068369; NCT02262455).||31068369|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|